81279 Jak2 gene trgt sequence alys
Also known as: JAK2 targeted sequencing, JAK2 full gene analysis
Janus Kinase 2 (JAK2) gene targeted sequencing analysis to identify known and novel mutations in myeloproliferative neoplasms.
In Plain Language
Blood cancer sequencing test; JAK2 mutation comprehensive test
Clinical Context
Comprehensive JAK2 analysis beyond common V617F mutation to detect rare variants that may affect myeloproliferative neoplasm diagnosis or treatment.
RVU Information
CPT 81279 does not have a physician work RVU assigned by CMS. Reimbursement for this code is determined by payer-specific fee schedules.
Billing & Documentation
Lab and pathology codes require an order from the treating provider with clinical indication. For molecular pathology and genetic testing, document the specific analytes tested and clinical rationale.
How This Code Compares
This code has a work RVU of 0.00, meaning it does not have a physician work component assigned by CMS. In the Pathology & Lab category, 94% of codes share this characteristic.
Specialties
Frequently Asked Questions
What is CPT code 81279?
CPT 81279 (Jak2 gene trgt sequence alys) is a Pathology & Lab code. Janus Kinase 2 (JAK2) gene targeted sequencing analysis to identify known and novel mutations in myeloproliferative neoplasms.
Who uses CPT code 81279?
CPT 81279 is used by Pathology, Hematology, Oncology. Comprehensive JAK2 analysis beyond common V617F mutation to detect rare variants that may affect myeloproliferative neoplasm diagnosis or treatment.
When is CPT 81279 used?
Comprehensive JAK2 analysis beyond common V617F mutation to detect rare variants that may affect myeloproliferative neoplasm diagnosis or treatment.
Track This Code in RVU Edge
Log procedures, calculate wRVUs, and benchmark against national data — all in one app.
CPT® is a registered trademark of the American Medical Association. Data sourced from CMS Physician Fee Schedule RVU26A. Descriptions, synonyms, and clinical context are original content by RVU Edge.